Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 445 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Licorice: The Unique Root With 10 Amazing Health Benefits August 21, 2019 Study Says Educational Materials for Chemo Often Require Higher Reading Level... September 25, 2019 Tepotinib Shows Activity in Advanced NSCLC with a MET Exon 14... September 9, 2020 Patients Treated With Chemotherapy and B Cell–Targeting Agents Show Impaired Serological... October 1, 2021 Load more HOT NEWS Taking Control – Risks vs. Benefits Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... Darolutamide Maintenance Improves Outcomes in Patients with mCRPC Who Were Previously... Isolated Hepatic Perfusion with Melphalan Improves Response Rate and PFS in...
